Published on : Nov 30, 2016
Albany, New York, November 30, 2016: Market Research Hub has recently announced the addition of a new report to its offerings. The report is titled as “CD22: a suitable antigen for targeted payload delivery by immunotherapeutics”. This study defines and assesses the competitive landscape of CD22-targeted immunotherapeutics based on different treatment modalities. In addition to this, it also describes the profiles of 16 different specific and Bi-specific anti-CD22 immunotherapeutics.
Bi-specific antibodies are those used to targets bind cell-surface as well as digoxigenin (Dig) and were generated for targeted payload delivery. Payloads include small compounds (Dig-Cy5, Dig-Doxorubicin) and proteins (Dig-GFP). Complex payloads are targeted by these bispecific antibodies to the cancer cells and since these complexes are stable in serum, so they can be applied for the targeted delivery.
Basically, CD22 is a regulatory molecule that prevents the over activation of the immune system and also prevents the development of autoimmune diseases. It is found on the surface of mature B cells and to a smaller extent on some immature B cells. CD22 expression occurs in more than 90% of patients with B-lineage acute lymphoblastic leukemia (A type of cancer). On the other hand, in B-cell non-Hodkgina lymphoma (NHL); CD22 expression ranges from 91% to 99% in the aggressive and idle populations, respectively. CD22 is not expressed on non-B lineage cells or hematopoietic stem cells. By immunotherapeutics such as antibodies or engineered T-cells, it acts as a suitable antigen for targeted payload delivery. It became rapidly internalized after binding of the anti-CD22 antibody and not shed in the extracellular environment. These features makes it an attractive antigen for targeted delivery. With the help of anti-CD22 antibody, research has demonstrated therapeutic activity in clinical trials of lymphoma, leukemia and autoimmune diseases. Also, treating currently over 1500 cases of non-Hodgkin lymphoma, acute lymphoblastic leukemias etc.
According to the report, Immunotherapy of NHL and ALL with naked anti-CD22 antibodies only achieved modest worth results indicating the need for more effective payloads, but at the same time also providing development opportunities for new treatment modalities such as:
- Immunotoxins (IT)
- Antibody-Dug Conjugates (ADC)
- Combination therapies
- Radioimmunotherapy (RIT)
- Chimeric Antigen Receptor (CAR) T-Cells
Click here to get more info with TOC in a PDF Format: http://www.marketresearchhub.com/enquiry.php?type=S&repid=873507
Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics are also analyzed in the report. Furthermore in the report, the profiles of nine companies that are active in the development of anti-CD22 immunotherapeutics are presented.
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org